-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Why Is Clovis Oncology (CLVS) Stock Up Today?
Why Is Clovis Oncology (CLVS) Stock Up Today?
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
In a still-fresh press release, Clovis Oncology (NASDAQ:CLVS) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to submit a supplemental New Drug Application (NDA) to the Food and Drug Administration (FDA) for a specific subgroup of prostate cancer patients and intends to discuss NDA submission for a broader patient population with the FDA. All in all, these developments are having a positive effect on CLVS stock today.
Clovis Oncology is a small biotechnology firm with a market capitalization of around $175 million. Yet, the company wants to make a big impact in combating prostate cancer.
To this end, Clovis is advancing a Phase 3 clinical trial for Rubraca, called TRITON3. As it turns out, Clovis Oncology discovered "significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR)" with Rubraca "compared with the control group." That control group was administered docetaxel, abiraterone acetate or enzalutamide.
That's not all, though. In 2023's first quarter, Clovis Oncology intends to submit a supplemental NDA to the FDA. This will be for the "BRCA subgroup of patients," which relates to breast cancer potentiality. Furthermore, Clovis plans to talk with the FDA about possibly submitting an NDA for "the broader ITT" or intent-to-treat population.
What's Happening With CLVS Stock?
CLVS stock wobbled quite a bit this morning. Specifically, it moved up as much as 4% before pulling back to a 2% daily gain. Perhaps, traders are still digesting all of the medical terminology and considering its implications.
Still, one doesn't have to be a medical professional to appreciate the progress that Clovis Oncology is making here. Prostate cancer has already taken too many men's lives. So, it's great news that Rubraca met its primary endpoint in this stage of the clinical trial.
Alan H. Bryce, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic, made an important point about this. "Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible," he advised.
Meanwhile, financial traders will want to know that "this trial clearly shows the value of rucaparib as a treatment for these men." Bryce clearly sees the significance of today's announcement from Clovis Oncology. It's up to Wall Street to decide whether CLVS stock will, in due time, move higher on the news.
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
Read More: Penny Stocks — How to Profit Without Getting Scammed
On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
David Moadel has provided compelling content – and crossed the occasional line – on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.
The post Why Is Clovis Oncology (CLVS) Stock Up Today? appeared first on InvestorPlace.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
InvestorPlace-股票市场新闻、股票建议和交易提示
In a still-fresh press release, Clovis Oncology (NASDAQ:CLVS) just announced that its Phase 3 trial for Rubraca, a prostate cancer treatment, achieved its primary endpoint. Moreover, Clovis plans to submit a supplemental New Drug Application (NDA) to the Food and Drug Administration (FDA) for a specific subgroup of prostate cancer patients and intends to discuss NDA submission for a broader patient population with the FDA. All in all, these developments are having a positive effect on CLVS stock today.
在一份仍然新鲜的新闻稿中,克洛维斯肿瘤学纳斯达克(Sequoia Capital:CLVS)刚刚宣布,其治疗前列腺癌Rubra的3期试验达到了主要终点。此外,Clovis计划向食品和药物管理局(FDA)提交一份针对前列腺癌患者特定亚组的补充新药申请(NDA),并打算与FDA讨论针对更广泛患者群体的NDA申请。总而言之,这些发展对今天的CLVS股票产生了积极的影响。
Clovis Oncology is a small biotechnology firm with a market capitalization of around $175 million. Yet, the company wants to make a big impact in combating prostate cancer.
Clovis Oncology是一家小型生物技术公司,市值约1.75亿美元。然而,该公司希望在抗击前列腺癌方面产生重大影响。
To this end, Clovis is advancing a Phase 3 clinical trial for Rubraca, called TRITON3. As it turns out, Clovis Oncology discovered "significantly improved radiographic progression-free survival (rPFS) by independent radiology review (IRR)" with Rubraca "compared with the control group." That control group was administered docetaxel, abiraterone acetate or enzalutamide.
为此,Clovis正在推进Rubra的第三阶段临床试验,称为TRITON3。事实证明,Clovis Oncology发现,与对照组相比,使用Rubra的“通过独立放射学审查(IRR)显著提高了放射学无进展存活率(RPFS)”。对照组给予多西紫杉醇、醋酸阿比特龙或苯扎鲁胺。
That's not all, though. In 2023's first quarter, Clovis Oncology intends to submit a supplemental NDA to the FDA. This will be for the "BRCA subgroup of patients," which relates to breast cancer potentiality. Furthermore, Clovis plans to talk with the FDA about possibly submitting an NDA for "the broader ITT" or intent-to-treat population.
不过,这还不是全部。在2023年的第一季度,Clovis Oncology打算向FDA提交一份补充NDA。这将是针对“BRCA患者亚组”的,这与乳腺癌的可能性有关。此外,克洛维斯计划与FDA讨论是否可能提交一份针对“更广泛的ITT”或意向治疗人群的NDA。
What's Happening With CLVS Stock?
CLVS股票怎么了?
CLVS stock wobbled quite a bit this morning. Specifically, it moved up as much as 4% before pulling back to a 2% daily gain. Perhaps, traders are still digesting all of the medical terminology and considering its implications.
今天上午,CLVS的股票出现了相当大的波动。具体地说,该指数一度上涨4%,随后回落至2%的单日涨幅。或许,交易员仍在消化所有的医学术语,并考虑其影响。
Still, one doesn't have to be a medical professional to appreciate the progress that Clovis Oncology is making here. Prostate cancer has already taken too many men's lives. So, it's great news that Rubraca met its primary endpoint in this stage of the clinical trial.
尽管如此,一个人不一定要是医学专业人士才能欣赏克洛维斯肿瘤学在这里取得的进展。前列腺癌已经夺走了太多男性的生命。因此,Rubra在临床试验的这个阶段达到了主要终点,这是一个好消息。
Alan H. Bryce, chair of the Division of Hematology and Medical Oncology at the Mayo Clinic, made an important point about this. "Men with this type of metastatic prostate cancer want to get their genetically targeted therapy as early as possible," he advised.
梅奥诊所血液学和内科肿瘤科主任艾伦·H·布莱斯对此提出了重要的观点。“患有这种类型转移性前列腺癌的男性希望尽早接受基因靶向治疗,”他建议说。
Meanwhile, financial traders will want to know that "this trial clearly shows the value of rucaparib as a treatment for these men." Bryce clearly sees the significance of today's announcement from Clovis Oncology. It's up to Wall Street to decide whether CLVS stock will, in due time, move higher on the news.
与此同时,金融交易员们想知道的是,“这项试验清楚地显示了鲁卡帕利作为治疗这些人的价值。”布莱斯清楚地看到了克洛维斯肿瘤学公司今天宣布的意义。消息传出后,CLVS的股价是否会在适当的时候走高,这取决于华尔街。
On Penny Stocks and Low-Volume Stocks: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That's because these "penny stocks" are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com's writers disclose this fact and warn readers of the risks.
关于细价股和低成交量股票:除了最罕见的例外, 不会发布关于市值低于1亿美元或每天交易量低于10万股的公司的评论。这是因为这些“廉价股”经常是诈骗艺术家和市场操纵者的游乐场。如果我们真的发表了对可能受我们评论影响的低成交量股票的评论,我们要求 InvestorPlace.com的作者披露这一事实,并警告读者风险。
Read More: Penny Stocks — How to Profit Without Getting Scammed
阅读更多信息: 细价股-如何在不上当的情况下获利
On the date of publication, David Moadel did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
在出版之日,大卫·莫德尔没有(直接或间接)持有本文所述证券的任何头寸。本文表达的观点是作者的观点,以InvestorPlace.com为准出版指南.
David Moadel has provided compelling content – and crossed the occasional line – on behalf of Motley Fool, Crush the Street, Market Realist, TalkMarkets, TipRanks, Benzinga, and (of course) InvestorPlace.com. He also serves as the chief analyst and market researcher for Portfolio Wealth Global and hosts the popular financial YouTube channel Looking at the Markets.
David Moadel代表Motley Fool、Crush the Street、Market Rests、TalkMarkets、TipRanks、Benzinga和(当然)InvestorPlace.com提供了令人信服的内容,偶尔也会越界。他还担任Portfolio Wealth Global的首席分析师和市场研究员,并主持广受欢迎的YouTube财经频道Look at the Markets。
The post Why Is Clovis Oncology (CLVS) Stock Up Today? appeared first on InvestorPlace.
为什么Clovis Oncology(CLVS)今天有库存?最先出现在InvestorPlace上。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧